FibroGen Inc

NASDAQ:FGEN   3:59:53 PM EDT
10.94
-0.27 (-2.41%)
Other Pre-Announcement

FibroGen Completes Patient Enrollment In Phase 3 Study Of Duchenne Muscular Dystrophy Treatment

Published: 06/08/2022 12:54 GMT
FibroGen Inc (FGEN) - Fibrogen Announces Completion of Patient Enrollment in Lelantos-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy.
Fibrogen Inc - Top-line Data From Lelantos-2 Study is Anticipated in 2h:2023.